IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Optimal Asset Management Inc.

Optimal Asset Management Inc. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,700 shares of the medical research company’s stock after acquiring an additional 300 shares during the quarter. Optimal Asset Management Inc.’s holdings in IQVIA were worth $908,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. TRU Independence Asset Management 2 LLC purchased a new position in IQVIA during the fourth quarter valued at approximately $27,000. Encompass Wealth Advisors LLC purchased a new position in IQVIA during the fourth quarter valued at approximately $27,000. CVA Family Office LLC purchased a new position in IQVIA during the first quarter valued at approximately $29,000. Wealthcare Advisory Partners LLC purchased a new position in IQVIA during the first quarter valued at approximately $33,000. Finally, Safeguard Investment Advisory Group LLC purchased a new position in IQVIA during the fourth quarter valued at approximately $34,000. Institutional investors own 86.31% of the company’s stock.

A number of analysts have recently commented on the company. Truist boosted their price objective on IQVIA from $235.00 to $260.00 in a research report on Monday, April 26th. Argus boosted their price objective on IQVIA from $220.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, May 12th. Canaccord Genuity boosted their price objective on IQVIA from $220.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, May 12th. boosted their price objective on IQVIA from $225.00 to $265.00 in a research report on Friday, April 23rd. Finally, Citigroup boosted their price objective on IQVIA from $225.00 to $265.00 in a research report on Friday, April 23rd. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. IQVIA presently has a consensus rating of “Buy” and an average price target of $248.84.

NYSE IQV opened at $243.03 on Thursday. The stock’s fifty day moving average is $242.00. The firm has a market capitalization of $46.58 billion, a price-to-earnings ratio of 115.73, a P/E/G ratio of 2.36 and a beta of 1.45. The company has a debt-to-equity ratio of 1.94, a current ratio of 1.15 and a quick ratio of 1.15. IQVIA Holdings Inc. has a fifty-two week low of $146.00 and a fifty-two week high of $254.05.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, April 22nd. The medical research company reported $2.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.85 by $0.33. The company had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.18 billion. IQVIA had a return on equity of 20.96% and a net margin of 3.40%. The firm’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.50 earnings per share. On average, equities research analysts predict that IQVIA Holdings Inc. will post 8.15 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: What is meant by holder of record?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.